Neurocrine to slash workforce
- Share via
From Times Wire Services
Neurocrine Biosciences Inc. said it would fire 130 employees, or more than half its workforce, to cut costs after its insomnia drug failed to win U.S. approval, leaving the company with no product to sell.
The San Diego company will have about 120 employees after the cutbacks, Neurocrine said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
